Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Hematology
•
Cardiology
•
Geriatric Medicine
In frail older adults on DOACs who meet only one formal dose-reduction criterion but have high bleeding risk, do you ever empirically reduce the dose?
Related Questions
How do you manage anticoagulation/antiplatelet therapies with strong indications for uninterrupted therapy in setting of urgent procedures?
For patients over 70 with elevated ASCVD risk but no prior cardiovascular events, do you ever recommend continuing or initiating low-dose aspirin?
What is your systolic blood pressure target for patients over 80 with frailty and multiple comorbidities?
How are you incorporating the newer RCT data suggesting no mortality benefit to indefinite beta-blocker therapy for patients who are several years out from an MI with preserved LVEF and no angina or arrhythmia?
How do you counsel an otherwise healthy patient on how soon they can go back to moderate exercise after a bilateral pulmonary embolism?
What is your approach to the management of chronic GI bleeding from AVMs in an elderly patient on DOAC for atrial fibrillation?
Do you recommend starting a statin in patients above 75 years old with diabetes but no known ASCVD?
What are some practical tips in distinguishing between metabolic bone disease due to chronic kidney disease and osteoporosis?
What is the role of MRI in assessing the risk of embolism in patients with persistent left ventricular thrombus following myocardial infarction?
How frequently would you consider IV iron treatment for ongoing iron loss and severe iron deficiency anemia?
